[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561509":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Illinois at Chicago","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Clemastine arm","EXPERIMENTAL","Participants in the clemastine arm of the study will receive clemastine 5.36 mg PO twice daily for 12 weeks. Based on clinical assessment, participants will also receive one of the following antidepressant medications: SSRI: Fluoxetine, sertraline, citalopram, escitalopram, vilazodone, vortioxetine SNRI: Venlafaxine, desvenlafaxine, duloxetine, levomilnacipran Augmentation: Bupropion and mirtazapine (monotherapy option in addition to first augmentation level), aripiprazole and quetiapine (second augmentation level).\n\nAllowable concomitant medications parallel clinical practice. These can include trazodone (up to 100mg nightly) for insomnia or as-needed use of benzodiazepines for concomitant anxiety, up to a maximum daily dose equivalent to lorazepam 2mg daily. Psychotropic medications used for other indications (such as tricyclics or gabapentin for pain) are allowable. Concomitant psychotherapy is allowed.",[13],"Drug: Clemastine Fumarate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo arm","PLACEBO_COMPARATOR","Participants in the placebo arm of the study will receive a placebo capsule PO twice daily for 12 weeks.",[19],"Drug: Placebo",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Clemastine Fumarate","Listed in arm\u002Fgroup description",[9],[27,28],"Clemastine","Tavist Allergy",{"type":22,"name":30,"description":24,"armGroupLabels":31,"otherNames":32},"Placebo",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Olu A Ajilore, MD, PhD","CONTACT","312-413-4562","oajilore@uic.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of Illinois College of Medicine","RECRUITING","Chicago","Illinois","60612","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-87.65005,41.85003,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":37,"phoneExt":32,"email":38},"Olusola Ajilore, MD, PhD",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Olusola Alade Ajilore","Professor. Director, Clinical Research Core\u002FCenter for Clinical and Translational Science",[62],{"name":63,"class":6},"Cures Within Reach","100561509","phase-2-clemastine-for-improving-white-matter-and-boosting-antidepressant-response-in-late-life-depression-100561509",false,"NCT06591091","Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","CLIMB","Inclusion Criteria:\n\n* Age \\> 60 years\n* Diagnosis of major depressive disorder, single or recurrent episode (DSM5)\n* Symptom Severity: MADRS ≥ 15\n* Seeking antidepressant treatment\n* Cognition score of MoCA \\>24\n* Fluent in English or Spanish\n\nExclusion Criteria:\n\n* Other Axis I psychiatric disorders, except for simple phobia or anxiety disorders present uniquely during the depressive episode (e.g., generalized anxiety disorder (GAD) or panic disorder symptoms)\n* History of alcohol or drug dependence or abuse in the last year\n* History of a developmental disorder or history of IQ (intelligence quotient) \\\u003C70\n* Acute suicidality ideation within the past month as determined by the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Acute grief (\\\u003C1 month)\n* Current or past psychosis\n* Primary neurological disorder, including dementia, clinical stroke, brain tumor, epilepsy, etc.\n* Presence of unstable medical illness requiring urgent treatment\n* Any MRI contraindication\n* Electroconvulsive Therapy (ECT) in last 6 months","ALL","60 Years",{"count":74,"type":75},80,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.",[81],"Depression",[83,84],"Late-life Depression","Antidepressant medication response","2026-06-26",{"date":87,"type":88},"2026-06-30","ACTUAL",{"date":90,"type":88},"2025-12-10",{"date":92,"type":75},"2026-12",{"name":5,"class":6},1]